| November 4, 2016 | Established Elix, Inc. in Shibuya-ku, Tokyo, Japan |
|---|
| December 15, 2017 | Participated in the Life Intelligence Consortium (LINC) |
|---|
| February 1, 2018 | The headquarters of Elix, Inc. was relocated to 4-3-1, Toranomon, Minato-ku, Tokyo, Japan |
|---|
| October 4, 2019 | Selected for “Blockbuster TOKYO”, an acceleration program for pharmaceutical and medical startups |
|---|
| November 1, 2019 | The headquarters of Elix, Inc. was relocated to Daini Togo Park Building, 8-34 Yonbancho, Chiyoda-ku, Tokyo, Japan |
|---|
| July 7, 2020 | Entered into a joint research project on AI drug discovery with Astellas Pharma Inc. |
|---|
| October 20, 2021 | Released kMoL, a machine learning library for AI drug discovery library with federated learning capabilities, jointly developed with Kyoto University |
|---|
| December 20, 2021 | Entered into a joint collaboration with Shionogi & Co., Ltd. for verification of practical retrosynthetic analysis |
|---|
| May 1, 2022 | Launched our AI drug discovery platform, Elix Discovery™, and started providing AI consulting and implementation support to KAKEN PHARMACEUTICAL CO., LTD. |
|---|
| April 1, 2025 | Entered into a strategic collaboration agreement with PRISM BioLab Co., Ltd. |
|---|
| July 8, 2025 | Commercialized an AI drug discovery platform that incorporates multiple AI models trained using federated learning on data provided by 16 pharmaceutical companies. |
|---|
| July 10, 2025 | Provided AI Drug Discovery Platform “Elix DiscoveryTM” to Eisai Co., Ltd. |
|---|
| August 7, 2025 | Provided AI Drug Discovery Platform “Elix DiscoveryTM” to KYORIN Pharmaceutical Co., Ltd. |
|---|
